Skip to content
Politically.com Search all
Menu

2026 · 2nd Quarter (Apr 1 - June 30)

KYVERNA THERAPEUTICS, INC.

Filed by AKIN GUMP STRAUSS HAUER & FELD.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-09-24 06:26:08 UTC.

Source-reported fields

Filing overview

Type
2nd Quarter - Report
Posted
Jul 20, 2026
Income
$60,000.00
Expenses
Not reported
Filing UUID
a9383920-bde3-4465-8e78-108141ef613d
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

Issues related to developing cell therapies for patients, including Stiff Person Syndrome, rare disease, and Multiple Sclerosis; Issues related to H.R. 8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027.

Literal federal measure citations: H.R. 8646

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.